Alterity Financial Group LLC Purchases 31 Shares of Eli Lilly and Company (NYSE:LLY)

Alterity Financial Group LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,364 shares of the company’s stock after purchasing an additional 31 shares during the period. Eli Lilly and Company accounts for approximately 1.1% of Alterity Financial Group LLC’s portfolio, making the stock its 26th biggest holding. Alterity Financial Group LLC’s holdings in Eli Lilly and Company were worth $795,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in LLY. Simon Quick Advisors LLC grew its stake in shares of Eli Lilly and Company by 10.5% in the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after acquiring an additional 278 shares during the last quarter. Liontrust Investment Partners LLP acquired a new stake in Eli Lilly and Company in the 3rd quarter worth $8,326,000. WASHINGTON TRUST Co increased its holdings in shares of Eli Lilly and Company by 16.5% during the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock worth $11,013,000 after purchasing an additional 2,671 shares during the period. Armstrong Fleming & Moore Inc acquired a new position in shares of Eli Lilly and Company during the second quarter valued at about $357,000. Finally, Redhawk Wealth Advisors Inc. lifted its stake in shares of Eli Lilly and Company by 0.9% in the third quarter. Redhawk Wealth Advisors Inc. now owns 6,986 shares of the company’s stock valued at $3,752,000 after buying an additional 65 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of several research reports. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Bank of America lifted their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, February 20th. Morgan Stanley lifted their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $689.52.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $777.96 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The stock has a market capitalization of $739.19 billion, a PE ratio of 134.13, a PEG ratio of 1.71 and a beta of 0.34. The firm has a 50 day moving average of $730.97 and a 200-day moving average of $637.01. Eli Lilly and Company has a 12 month low of $334.58 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the prior year, the business earned $2.09 earnings per share. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. On average, equities research analysts predict that Eli Lilly and Company will post 12.42 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 14,388 shares of Eli Lilly and Company stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $630.28, for a total transaction of $9,068,468.64. Following the sale, the insider now directly owns 99,754,422 shares of the company’s stock, valued at $62,873,217,098.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 195,055 shares of company stock valued at $125,254,657 in the last 90 days. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.